ATE368660T1 - Verfahren zur herstellung von enantiomerisch reine beta-d-dioxolan-nukleoside - Google Patents

Verfahren zur herstellung von enantiomerisch reine beta-d-dioxolan-nukleoside

Info

Publication number
ATE368660T1
ATE368660T1 AT01203571T AT01203571T ATE368660T1 AT E368660 T1 ATE368660 T1 AT E368660T1 AT 01203571 T AT01203571 T AT 01203571T AT 01203571 T AT01203571 T AT 01203571T AT E368660 T1 ATE368660 T1 AT E368660T1
Authority
AT
Austria
Prior art keywords
enantiomerically pure
nucleosides
pure beta
dioxolane nucleosides
dioxolane
Prior art date
Application number
AT01203571T
Other languages
English (en)
Inventor
Chung K Chu
Raymond F Schinazi
Original Assignee
Univ Georgia Res Found
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia Res Found, Univ Emory filed Critical Univ Georgia Res Found
Application granted granted Critical
Publication of ATE368660T1 publication Critical patent/ATE368660T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01203571T 1990-12-05 1991-12-05 Verfahren zur herstellung von enantiomerisch reine beta-d-dioxolan-nukleoside ATE368660T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/622,762 US5179104A (en) 1990-12-05 1990-12-05 Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides

Publications (1)

Publication Number Publication Date
ATE368660T1 true ATE368660T1 (de) 2007-08-15

Family

ID=24495427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01203571T ATE368660T1 (de) 1990-12-05 1991-12-05 Verfahren zur herstellung von enantiomerisch reine beta-d-dioxolan-nukleoside

Country Status (9)

Country Link
US (1) US5179104A (de)
EP (4) EP1164133B1 (de)
JP (3) JP3421335B2 (de)
AT (1) ATE368660T1 (de)
AU (2) AU9147591A (de)
CA (2) CA2590125A1 (de)
DE (1) DE69133576T2 (de)
ES (1) ES2291268T3 (de)
WO (1) WO1992010497A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2637774C (en) 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ATE346651T1 (de) * 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
ATE267198T1 (de) * 1997-03-19 2004-06-15 Univ Emory Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
ES2314157T3 (es) * 1998-11-02 2009-03-16 Gilead Sciences, Inc. Terapia de combinacion para tratar el virus de la hepatitis b.
DK1140937T3 (da) * 1998-12-23 2004-03-22 Shire Biochem Inc Antivirale nucleosid-analoger
US6511983B1 (en) 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
PT1574512E (pt) 2001-03-01 2008-03-05 Abbott Lab Formas polimórficas e outras formas cristalinas de cis-ftc
AU2003296360A1 (en) * 2002-12-09 2004-06-30 Emory University Dioxolane thymine and combinations for use against 3tc/ azt resistant strains of hiv
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
DE10335061B4 (de) * 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
CN101044122A (zh) * 2004-02-03 2007-09-26 埃莫里大学 制备1,3－二氧戊环核苷的方法
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2009052050A1 (en) * 2007-10-15 2009-04-23 Pharmasset, Inc. Dioxolane thymine phosphoramidates as anti-hiv agents
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
JP6104504B2 (ja) 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
ES2477228T3 (es) 2009-12-22 2014-07-16 Bridgestone Corporation Composición mejorada de un modificador vin�lico y procedimientos para utilizarla
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
CN103351414B (zh) * 2013-06-19 2016-06-01 河南中烟工业有限责任公司 烟用保润剂1-o-羟乙基-d-吡喃甘露糖及其制备方法
WO2015005961A1 (en) 2013-07-12 2015-01-15 Emd Millipore Corporation A method of determining virus removal from a sample containing a target protein using activated carbon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9103544D0 (en) * 1991-02-20 1991-04-10 Alcan Int Ltd Coating powders

Also Published As

Publication number Publication date
EP0562009A4 (en) 1993-11-24
ES2291268T3 (es) 2008-03-01
DE69133576T2 (de) 2008-04-17
US5179104A (en) 1993-01-12
JPH07502973A (ja) 1995-03-30
CA2099589A1 (en) 1992-06-06
JP2007008959A (ja) 2007-01-18
JP2001097973A (ja) 2001-04-10
EP1164133A3 (de) 2002-01-02
JP3881165B2 (ja) 2007-02-14
WO1992010497A1 (en) 1992-06-25
EP1164133B1 (de) 2007-08-01
CA2590125A1 (en) 1992-06-25
AU1664097A (en) 1997-07-17
EP1164133A2 (de) 2001-12-19
EP1600448A3 (de) 2006-08-23
AU9147591A (en) 1992-07-08
JP3421335B2 (ja) 2003-06-30
EP1600448A2 (de) 2005-11-30
CA2099589C (en) 2007-08-21
EP1693373A1 (de) 2006-08-23
DE69133576D1 (de) 2007-09-13
AU714646B2 (en) 2000-01-06
JP4280276B2 (ja) 2009-06-17
EP0562009A1 (de) 1993-09-29

Similar Documents

Publication Publication Date Title
DE69133576D1 (de) Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside
DE3575050D1 (de) Verfahren zur herstellung einer monolitisch-integrierten, optischen schaltung enthaltend einen laser und eine nach diesem verfahren erhaltene schaltung.
DE68907783D1 (de) Verfahren zur herstellung von fluorierten aethern.
DE69101775D1 (de) Verfahren zur Herstellung von Wasserstoffperoxid.
DE3860671D1 (de) Verfahren zur herstellung von 2,6-dialkylnaphthalin.
DE3680454D1 (de) Verfahren zur herstellung von halogenhaltigen (2,2)-paracyclophanen.
DE59007171D1 (de) Verfahren zur herstellung von sclareolid.
DE3778324D1 (de) Verfahren zur herstellung von organischen perfluoro-verbindungen.
DE3861825D1 (de) Verfahren zur herstellung von (2,2)-paracyclophan.
DE3585109D1 (de) Verfahren zur herstellung von (+/-)-3a,6,6,9a-tetramethylperhydronaphtho(2,1-b)furan.
DE3785530D1 (de) Verfahren zur herstellung von l-arginin.
DE3381203D1 (de) Verfahren zur herstellung von uridindiphosphat-n-acetylgalactosamin.
DE68916035D1 (de) Verfahren zur selektiven herstellung von 2,6-dialkylnaphthalenen.
DE3875008D1 (de) Verfahren zur herstellung von nitrilen.
DE69300551D1 (de) Verfahren zur Herstellung von (3R,4R)-3-Hydroxy-4-Hydroxymethyl-4-Butanolid.
ATA390784A (de) Verfahren zur herstellung von neuem haeminarginat bzw. haeminlysinat
DE69204417D1 (de) Verfahren zur Herstellung von Epoxiden.
DE3879843D1 (de) Verfahren zur herstellung von 3,5,5-trimethylcyclohexa-2-en-1,4-dion.
DE3765129D1 (de) Verfahren zur herstellung von nitrilen.
DE3851306D1 (de) Verfahren zur Herstellung von optisch-aktiven 1,2-Diolen.
DE3578879D1 (de) Verfahren zur herstellung von 1,3-dimethyl-2-imidazolidinon.
DE3871591D1 (de) Verfahren zur herstellung von 1-propargyl-2,4-dioxoimidazolidin.
DE3874496D1 (de) Verfahren zur herstellung von 4,4'-dibrombiphenyl.
DE59104221D1 (de) Verfahren zur Herstellung von 2,3,5-Trimethyl-p-benzochinon.
DE69203106D1 (de) Verfahren zur Enthalogenierung von 1,3-Dioxolane.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties